Biological therapies in paediatric Behçet’s disease: results of an international collaborative study by the Pediatric Rheumatology European Society (PRES) Vasculitis Working Party
Authors' conclusion
Biologic therapies exhibit robust efficacy and an acceptable safety profile in pedBD.
Study context
- Population
- Paediatric Behçet's disease (BD) patients diagnosed before 18 years of age treated with biologics, PRES vasculitis study group, 19 centres across six countries
- Participants
- 109 patients19 centres6 countries
- Exposure
- Turkish vs European cohorts; ADA vs infliximab (IFX)
- Turkeyn = 64
- Europen = 45reference
- Outcome
- Indications for biologic therapies, and their efficacy, safety and remission rates
Methodological detailsmulticentre, international
- Multicentre
- International
Main finding
As reported in the abstract
Primary indications for initiating biologics
- Ocular involvement
- 40.4%
- Mucocutaneous involvement
- 22.9%
- Neurologic involvement
- 17.4%
- TNF-α inhibitors used
- 90.8%
- ADA (patients)
- 59
- IFX (patients)
- 38
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Skin involvement, Turkish vs European cohortMore common in Turkish cohort | P < 0.01 |
| Remission and disease activity decline, ADA vs IFX | P = 0.2 |
- Remission and disease activity decline, ADA vs IFX: faster decline in disease activity scores with ADA, not significant
Skin involvement, Turkish vs European cohort
- Other organ/system involvement similar
- Interval from symptom onset to diagnosis longer in European group
- Biologics initiated earlier and longer duration in European cohort (not significant)
Remission and disease activity decline, ADA vs IFX
- Remission rates similar with ADA and IFX
Safety
Serious infection
- Only one serious infection reported
- 1
Malignancy/autoimmune disease
- No malignancy/autoimmune disease observed
Original publication
Biological therapies in paediatric Behçet’s disease: results of an international collaborative study by the PRES Vasculitis Working Party. Rheumatology (Oxford). Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →